Dec 9 (Reuters) - Olema Pharmaceuticals Inc OLMA.O:
OLEMA ONCOLOGY ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR OP-3136, A POTENT KAT6 INHIBITOR
OLEMA PHARMACEUTICALS INC - PHASE 1 CLINICAL TRIAL FOR OP-3136 TO START EARLY 2025
Source text: ID:nGNX8Vj6ws
Further company coverage: OLMA.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.